Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens

Atopic Dermatitis Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Montelukast (Singulair) in Participants Ages 1 - 8 Years Diagnosed With Atopic Dermatitis Induced by Food Allergens

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00557284
• Other study ID #: 32032
• Status: Completed
• Phase: Phase 4
• First received: November 9, 2007
• Last updated: March 31, 2015
• Start date: March 2008
• Est. completion date: May 2009

Study information

• Verified date: March 2015
• Source: IMMUNOe International Research Centers
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

AD is a disease found in children; the focus of the study is the mechanisms associated in children with AD induced by food allergies.

This study will be a randomized, double-blind, placebo-controlled, parallel group trial conducted in participants diagnosed with atopic dermatitis and food allergies. The study duration for participants will be approximately 9 weeks. A total of 20 participants will be recruited for the entire study. Each arm will consist of 10 participants.The study will enroll 20 children, male or female, 1 - 8 years of age with atopic dermatitis (AD) associated with food allergens, previously documented by skin or RAST test, before enrollment. Atopic dermatitis and gastrointestinal (GI) symptoms will be scored and followed throughout the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: May 2009
• Est. primary completion date: May 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 1 Year to 8 Years

Eligibility

Inclusion Criteria:

1. Mild to moderate atopic dermatitis involving greater than or equal to 5% of body surface

2. Total severity score of 2 or greater for any 3 of the 4 signs and symptoms calculated by study doctor (erythema, papulation, or lichenification)

3. Positive skin or (radioallergosorbent) RAST tests by ImmunoCap to food or environmental allergens

4. GI symptoms total score of 2 by caregiver on GSRS scale revised for pediatrics

Exclusion Criteria:

1. Participants with intolerance or allergy to montelukast.

2. History of anaphylaxis requiring hospitalization.

3. No underlying renal or liver disease.

4. Participants with a diagnosis of severe asthma.

5. Participants diagnosed with primary immune deficiency.

6. Participants using sublingual immunotherapy.

7. Immunotherapy must be a maintenance dose for a minimum of 30 days.

8. If on gastrointestinal medication, 30 day stable dose before visit 1 and maintained throughout the study.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Atopic Dermatitis
• Dermatitis
• Dermatitis, Atopic
• Eczema

Intervention

Drug:
• Montelukast
4 mg oral granules for ages 12 - 23 months; 4 mg chewable tablet for 2 - 5 years of age; or 5 mg chewable tablet for 6 - 8 years of of age
• Placebo
Oral granules or chewable tablet, PO QD (given oral daily)

Locations

Country	Name	City	State
United States	1st Allergy & Clinical Research Centers	Centennial	Colorado
United States	1st Allergy & Clinical Research Centers	Thornton	Colorado

Sponsors (1)

Lead Sponsor	Collaborator
1st Allergy & Clinical Research Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Percentage of Body Involvement	Change in percentage of body involvement from baseline to study visit 4 (week 1 compared to week 9) for all subjects in each arm for AD as measured by study investigator	Baseline and 9 weeks	No
Primary	Mean Change in Investigator Global Assessment (IGA)	The mean change in IGA from baseline to study visit 4 (week 1 compared to week 9) for all subjects in each arm. The IGA is a six-point measure of disease severity and is evaluated by the investigator based on the overall assessment of skin lesions: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, 5= very severe.	Baseline and 9 weeks	No
Primary	Mean Change in PADC (Caregivers Perception of Disease Control)	Mean change in PADC from baseline to study visit 4 (week 1 compared to week 9) for all subjects in each arm. Caregiver's evaluation of disease control over the previous 7 days and will consist of a four-point scale ranging from complete control (0) to uncontrolled disease (3)	Baseline and 9 weeks	No
Primary	Mean Change in Pruritus	Mean change in pruritus scores from baseline to study visit 4 (week 1 compared to week 9) for all subjects in each arm. Pruritus assessments ("itch") will be recorded for the previous 24 hours using a 4 point-scale, ranging from none (0) to severe (3). Scores are cumulative per week.	Baseline and 9 weeks	No
Primary	Mean Change in Weekly Use of Rescue Medication for AD Flare-up - Cetirizine and/or 10% Hydrocortisone Cream	Average of weekly use of cetirizine and/or 10% hydrocortisone cream will be compared for all subjects in each arm from week 1 to week 9. Flare-up is defined as a worsening of the disease that is unacceptable to the participants and leads to second line topical steroid use and/or liquid anti-histamine use. Measurement is noted as 1 for daily use (does not correspond to multiple uses per day).	Baseline and 9 weeks	No
Secondary	Mean Change in Serum and Urinary Inflammatory Marker Levels	Mean change in levels from baseline to study visit 4 (week 1 compared to week 9)for interleukin 3 (IL3), tumor necrosis factor alpha (TNF alpha), nerve growth factor (NGF), and urinary leukotriene E4 (LTE4)	Baseline and 9 weeks	No
Secondary	Mean Change in Serum IgE Levels	Mean change in serum levels of IgE from baseline to study visit 4 (week 1 compared to week 9) for all subjects in each arm.	Baseline and 9 weeks	No
Secondary	Mean Change in (Gastrointestinal Symptom Rating Scale) GSRS	The mean change from baseline to study visit 4 (week 1 compared to week 9) in GRGS scores (GI symptoms will be recorded on *GSRS validated scale adjusted for pediatrics (*Gastrointestinal Symptoms in Patients with Irritable Bowel Syndrome and Peptic Ulcer Disease) for all subjects in each arm.This scale measures 7 different GI symptoms (1. abdominal pain; 2. nausea and vomiting; 3. abdominal dissention; 4. decreased passage of stools; 5. increased passage of stools; 6. loose stools; 7. hard stools) with severity ranges from 0 - 3 for each point (0 being no complaint and 3 being most severe for a maximum total of 21).	Baseline and 9 weeks	No

External Links

•   Research website